JNJ-40411813

Generic Name: JNJ-40411813

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O

CAS Number: 1127498-03-6

Unique Ingredient Identifier: 612BYT76F3

Background: JNJ-40411813 has been used in trials studying the treatment and basic science of Confusion, Schizophrenia, Perceptual Disorders, and Major Depressive Disorder.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Phase 2

Completed

Conditions: Focal Onset Seizures

Interventions: Drug: JNJ-40411813
Drug: Placebo

First Posted Date: 2021-04-08

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 110

Registration Number: NCT04836559

Locations: 🇷🇺
Specialized clinical psychiatric hospital #1, Krasnodar, Russian Federation
🇷🇺
Clinical City Hospital #1, Moscow, Russian Federation
🇷🇺
Nizny Novgorod clinical psychiatric hospital 1, Nizny Novgorod, Russian Federation

and more 66 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy